ESR1 and breast carcinoma: To investigate if JEKHT also increases sensitivity of endocrine-resistant human breast cancer cells to TAM, we treated endocrine-resistant ER+ LCC9 breast cancer cells with 1.6 mg/mL JEKHT and increasing doses of 4-OHT in vitro.